Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Perez-Soler on Treatment Options for NSCLC

February 14th 2012

Dr. Roman Perez-Soler, from Montefiore Medical Center, on Treatment Options for NSCLC

Radiation Therapy After Surgery Shows No Survival Benefit for Elderly Lung Cancer Patients

February 13th 2012

Many older patients with stage III lung cancer who received radiation therapy fared no better than those who did not receive radiation therapy.

Changing Paradigms for NSCLC in Personalized Therapy Era

January 20th 2012

With the discovery of mutation drivers for NSCLC--including EGFR, KRAS, and EMLA 4-ALK--targeted therapies directed to those mutations are beginning to make a difference.

Continuing Chemotherapy to Near Death Offers No Benefits in Older Patients With Advanced Lung Cancer

January 19th 2012

An aggressive approach to care involving the continuation of chemotherapy within 2 weeks of death does not improve survival in elderly patients with metastatic NSCLC.

SCLC on the Wane, but Difficult to Treat

January 18th 2012

Patients with limited and extensive SCLC show incremental gains with different treatment strategies but so far novel agents have failed to make a difference in outcomes.

No Survival Advantage for High-Dose Radiation Versus Standard-Dose Radiation in Stage III NSCLC

January 11th 2012

High-dose radiation was no better than standard-dose radiation given concurrently with chemotherapy in extending survival of patients with advanced unresectable NSCLC.

Patients With Lung Cancer Often Receive Excess Radiation

January 4th 2012

Patients undergoing lung resection for NSCLC are frequently exposed to a higher dose of radiation than that which has been deemed safe for healthcare workers.

Dr. Belani Discusses NSCLC Adjuvant Therapy

January 3rd 2012

Dr. Chandra Belani, from the Penn State Hershey Cancer Institute, Discusses NSCLC Adjuvant Therapy

Biomarker Identifies Patients With Advanced Lung Cancer Who Will Gain Most From Add-On Cetuximab

December 22nd 2011

Investigators reported that high tumor EGFR expression is a predictive biomarker that defines patients with advanced NSCLC who are most likely to derive a survival benefit from the addition of cetuximab to platinum-based, first-line chemotherapy.

Hospitals for Vulnerable Patients Less Likely to Provide Optimal Lung Cancer Care

December 19th 2011

New data show that patients treated for lung cancer at high safety-net burden hospitals undergo curative-intent surgery significantly less often than individuals treated at low safety-net burden facilities.

5 Questions for Martin Steffen, MD, PhD

December 15th 2011

Martin Steffen, MD, PhD, developed phosphorylation signatures that discriminate between lung tumors and normal lung, and is developing signatures for the prediction of therapy response.

Maintenance Therapy With Bevacizumab/Pemetrexed Appears Superior to Bevacizumab Alone

December 14th 2011

Maintenance therapy with bevacizumab plus pemetrexed achieved a 4-month benefit in progression-free survival (PFS) versus bevacizumab maintenance therapy alone.

Poster Session Highlights: 12th International Lung Cancer Congress

November 21st 2011

A highlight of 3 poster sessions from the 12th International Lung Cancer Congress on August 12, 2011 in Carlsbad, CA.

Adjusting Chemotherapy in Octogenarians With NSCLC

November 21st 2011

In the United States, the incidence of lung cancer has increased in those aged >74 years and will likely continue to rise.

The National Lung Screening Trial: Where Do We Go From Here?

November 14th 2011

A conversation with Denise R. Aberle, MD, on the National Lung Screening Trial (NLST) at the 12th International Lung Cancer Congress.

3 ASCO Updates Tackle Treatment and Supportive Care Questions

November 4th 2011

ASCO endorses a Canadian agency's outlook on ovarian ablation, chemotherapy limits for stage IV lung cancer patients, and supportive care antiemetic therapies.

Dr. Langer Discusses the PARAMOUNT Study

November 2nd 2011

Dr. Corey Langer from the Abramson Cancer Center Discusses the PARAMOUNT Study

Dr. Yung Discusses Forming a Multidisciplinary Team

October 31st 2011

Dr. Rex Yung from Sidney Kimmel Comprehensive Cancer Center Discusses Forming a Multidisciplinary Team

Dr. Mills Gives Examples of Unexpected Drug Responses

October 28th 2011

Dr. Gordon Mills from MD Anderson Cancer Center Gives Examples of Unexpected Therapy Responses

Dr. Scagliotti Gives 3 Important Lung Cancer Takeaway Points

October 27th 2011

Dr. Giorgio Scagliotti from the University of Turin Gives 3 Important Lung Cancer Takeaway Points